Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 2/20 | 0.51 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.51 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.51 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.51 |
| ▸ | TERT | O14746 | 2/20 | 0.44 |
| ▸ | METAP2 | P50579 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 3/20 | 0.44 |
| ▸ | NPC1 | O15118 | 2/20 | 0.44 |
| ▸ | PKM | P14618 | 1/20 | 0.44 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.42 |
| ▸ | PIK3CB | P42338 | 2/20 | 0.42 |
| ▸ | PIK3CG | P48736 | 2/20 | 0.42 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.42 |
| ▸ | PI4KA | P42356 | 1/20 | 0.42 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | CCNB2 | O95067 | 1/20 | 0.42 |
| ▸ | CDK1 | P06493 | 1/20 | 0.42 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21984930 | 0.89 | CYP2D6 (0.55) | CYP19A1CYP2D6CYP2C9CYP2C19TERT | |
| SCHEMBL11541937 | 0.89 | CYP2D6 (0.60) | CYP19A1CYP2D6CYP2C9CYP2C19METAP2 | |
| SCHEMBL17486063 | 0.83 | RAB9A (0.49) | CYP19A1CYP2D6CYP2C9CYP2C19TERT | |
| SCHEMBL8700941 | 0.82 | CYP2D6 (0.60) | CYP19A1CYP2D6CYP2C9CYP2C19TERT | |
| SCHEMBL28105489 | 0.81 | ALOX5AP (0.55) | CYP19A1CYP2D6CYP2C9CYP2C19TERT | |
| SCHEMBL15522518 | 0.81 | CYP11B1 (0.58) | CYP19A1CYP2D6CYP2C9CYP2C19RAB9A | |
| SCHEMBL17746913 | 0.81 | CYP19A1 (0.42) | CYP19A1CYP2D6CYP2C9CYP2C19TERT | |
| SCHEMBL29683245 | 0.79 | CYP19A1 (0.52) | CYP19A1CYP2D6CYP2C9CYP2C19METAP2 | |
| SCHEMBL17246864 | 0.79 | CYP19A1 (0.52) | CYP19A1CYP2D6CYP2C9CYP2C19METAP2 | |
| SCHEMBL19933562 | 0.79 | METAP2 (0.52) | METAP2RAB9ANPC1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117946084-A | Linear aza D-A type nonlinear optical material, and preparation method and application thereof | 浙江工业大学 | 2024-04-30 | — | — | CN | claimed |
| CN-114354595-A | Organic acidity detection agent and method, test paper, preparation method and application | 南京艾姆材料科技有限公司 | 2022-04-15 | — | — | CN | claimed |
| EP-4051667-B1 | HETEROCYCLIC CARBOXYLATE COMPOUNDS AS GLYCOLATE OXIDASE INHIBITORS | LILAC THERAPEUTICS INC (US) | 2026-01-28 | — | — | EP | disclosed |
| CN-114929676-B | Heterocyclic carboxylate compounds as glycolate oxidase inhibitors | 紫丁香疗法有限公司 | 2025-04-29 | — | — | CN | disclosed |
| US-20250064787-A1 | Heterocyclic Carboxylate Compounds as Glycolate Oxidase Inhibitors | LILAC THERAPEUTICS INC (US) | 2025-02-27 | — | — | US | disclosed |
| US-12168002-B2 | Heterocyclic carboxylate compounds as glycolate oxidase inhibitors | Lilac Therapeutics, Inc. (US) | 2024-12-17 | — | — | US | disclosed |
| EP-4470538-A2 | HETEROCYCLIC CARBOXYLATE COMPOUNDS AS GLYCOLATE OXIDASE INHIBITORS | Lilac Therapeutics, Inc. (US) | 2024-12-04 | — | — | EP | disclosed |
| CN-117946084-A | Linear aza D-A type nonlinear optical material, and preparation method and application thereof | 浙江工业大学 | 2024-04-30 | — | — | CN | disclosed |
| US-20240091200-A1 | Heterocyclic Carboxylate Compounds as Glycolate Oxidase Inhibitors | Lilac Therapeutics, Inc. | 2024-03-21 | — | — | US | disclosed |
| US-11806335-B2 | Heterocyclic carboxylate compounds as glycolate oxidase inhibitors | Lilac Therapeutics, Inc. (US) | 2023-11-07 | — | — | US | disclosed |
| US-11806335-B2 | Heterocyclic carboxylate compounds as glycolate oxidase inhibitors | Lilac Therapeutics, Inc. (US) | 2023-11-07 | — | — | US | disclosed |
| US-20170299530-A1 | COMPOUNDS AND METHODS FOR ANALYSIS AND SYNTHESIS OF SACCHARIDE COMPOUNDS, AND METHOD FOR QUANTITATING SACCHARIDE | ACADEMIA SINICA (TW) | 2017-10-19 | — | — | US | disclosed |
| WO-2017011531-A2 | ORGANIC LIGHT-EMITTING DIODE MATERIALS | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2017-01-19 | — | — | WO | disclosed |
| US-20150168415-A1 | COMPOUNDS AND METHODS FOR ANALYSIS AND SYNTHESIS OF SACCHARIDE COMPOUNDS | ACADEMIA SINICA (TW) | 2015-06-18 | — | — | US | disclosed |
| US-7867980-B2 | Lincosamide derivatives and antimicrobial agents comprising the same as active ingredient | MEIJI SEIKA KAISHA, LTD. (JP) | 2011-01-11 | — | — | US | disclosed |
| US-20100184746-A1 | LINCOSAMIDE DERIVATIVES AND ANTIMICROBIAL AGENTS COMPRISING THE SAME AS ACTIVE INGREDIENT | MEIJI SEIKA KAISHA LTD | 2010-07-22 | — | — | US | disclosed |
| EP-2166015-A1 | LINCOSAMIDE DERIVATIVE, AND ANTIBACTERIAL AGENT COMPRISING THE SAME AS ACTIVE INGREDIENT | Meiji Seika Kaisha Ltd. (JP) | 2010-03-24 | — | — | EP | disclosed |
| US-5780473-A | Substituted biphenyl sulfonamide endothelin antagonists | BRISTOL-MYERS SQUIBB COMPANY (US) | 1998-07-14 | — | — | US | disclosed |
| US-5760038-A | Substituted biphenyl sulfonamide endothelin antagonists | BRISTOL-MYERS SQUIBB COMPANY (US) | 1998-06-02 | — | — | US | disclosed |
| EP-0725067-A1 | Substituted biphenyl sulfonamide endothelin antagonists | BRISTOL-MYERS SQUIBB COMPANY (US) | 1996-08-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240091200-A1 | Heterocyclic Carboxylate Compounds as Glycolate Oxidase Inhibitors | UGDH, PGD, PNPO | CYP19A1 1204/4885CYP2D6 375/4885CYP2C9 349/4885 |
| US-11806335-B2 | Heterocyclic carboxylate compounds as glycolate oxidase inhibitors | UGDH, PGD, PNPO | CYP19A1 1204/4885CYP2D6 375/4885CYP2C9 349/4885 |
| US-20150168415-A1 | COMPOUNDS AND METHODS FOR ANALYSIS AND SYNTHESIS OF SACCHARIDE COMPOUNDS | MPI, GPI, FUT6 | CYP19A1 3209/4885CYP2D6 660/4885CYP2C9 1952/4885 |
| US-12168002-B2 | Heterocyclic carboxylate compounds as glycolate oxidase inhibitors | UGDH, PGD, PNPO | CYP19A1 1204/4885CYP2D6 375/4885CYP2C9 349/4885 |
| US-20250064787-A1 | Heterocyclic Carboxylate Compounds as Glycolate Oxidase Inhibitors | GLS, DUOX1, HAO1 | CYP19A1 1689/4885CYP2D6 779/4885CYP2C9 446/4885 |
| US-20100184746-A1 | LINCOSAMIDE DERIVATIVES AND ANTIMICROBIAL AGENTS COMPRISING THE SAME AS ACTIVE INGREDIENT | SIRT6, LAS1L, MRPS18A | CYP19A1 3584/4885CYP2D6 816/4885CYP2C9 1226/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.